( didates may be capable of finding ande...)Publication Confirms that EpCAM, the Target for Two of Micromet's,Product Candidates, Is Overexpressed on Cancer Stem Cells of,Certain Cancers,Health

didates may be capable of finding and eradicating cancer stem cells in various indications," commented Patrick Baeuerle, Ph.D., Micromet's Chief Scientific Officer. "In addition, EpCAM is also expressed on the progeny of cancer stem cells, which may lead to a reduction of tumor mass by these drugs alone or by combining them with standard therapies."

    References

    1  Dalerba P, Dylla SJ, Park I-K et al. Phenotypic characterization of

       human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007;

       104:10158-63

    2  Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and

       expansion of human colon-cancer-initiating cells. Nature 2007;

       445: 111-15

    3  Al-Hajj M, Wicha MS, Benito-Hernandez A et al. Prospective

       identification of tumorigenic breast cancer cells. Proc Natl Acad Sci

       USA 2003; 100: 3983-88

    4  Li C, Heidt DG, Dalerba P et al. Identification of pancreatic cancer

       stem cells. Cancer Res 2007; 67: 1030-7

    5  Collins AT, Berry PA, Hyde C et al. Prospective identification of

       tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-51

    6  Pan CX, Zhu W, Cheng L. Implications of cancer stem cells in the

       treatment of cancer. Future Oncol 2006; 2: 723-31

    7  Baeuerle PA, Gires 0. EpCAM (CD326) finding its role in cancer. Brit J

       Cancer 2007; 96: 417-23

    8  Went P, Vasei M, Bubendorf L et al. Frequent high-level expression of

       the immunotherapeutic target Ep-CAM in colon, stomach, prostate and

       lung cancers. Br J Cancer 2006; 94: 128-135

About Micromet, Inc. (www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases. Two product candidates are currently in clinical trials. MT103/MEDI-538, which is the first pro
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
2. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
3. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
4. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
5. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
6. Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma
7. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
8. Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data at ASCO
9. Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database
10. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
11. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex